MannKind Previews Pediatric, Pregnancy Data for Afrezza Ahead of FDA Decision

Event summary

  • MannKind to present nine posters on Afrezza at ADA 2026, including pediatric efficacy, pregnancy use, and AID system compatibility.
  • FDA target action date for Afrezza pediatric approval set for May 29, 2026.
  • New data compares Afrezza to rapid-acting insulin analogs in children, gestational diabetes patients.
  • Late-breaking comparative data vs. rapid-acting insulin analogs to be presented June 7.
  • Afrezza first needle-free insulin option for pediatric patients if approved.

The big picture

MannKind's push to expand Afrezza's use into pediatric and gestational diabetes populations comes as automated insulin delivery systems gain traction. The company aims to position its inhaled insulin as a needle-free alternative in these underserved segments, potentially disrupting the $45 billion global diabetes drug market. Success would depend on both regulatory approval and clinician acceptance of the new data.

What we're watching

Regulatory Outcome
Whether the FDA will approve Afrezza for pediatric use by the May 29, 2026 target date, potentially opening a new market segment.
Clinical Adoption
How pediatricians and endocrinologists will respond to Afrezza data in comparison to existing rapid-acting insulin options.
Market Expansion
The pace at which MannKind can commercialize Afrezza in pediatric care if approved, including payer coverage and prescribing patterns.

Related topics

Medical Devices